RxSight's Strong Q1 Performance and Market Expansion Justify Buy Rating
What 10 Analyst Ratings Have To Say About RxSight
Oppenheimer Remains a Buy on RxSight (RXST)
RxSight Outperforms With Strong Q1 Results and Raised Guidance: Buy Rating Affirmed
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)
RxSight Analyst Ratings
Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and BioMarin Pharmaceutical (BMRN)
RxSight Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)
Patrick Wood Reaffirms Buy Rating for RxSight Amid Strong Growth and Market Expansion Potential
RxSight Analyst Ratings
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating
Oppenheimer Reaffirms Their Buy Rating on RxSight (RXST)
Buy Rating on RxSight: Strong Financials and Positive 2024 Outlook Drive Upward Price Target
Analysts Are Bullish on Top Healthcare Stocks: RxSight (RXST), Personalis (PSNL)
RxSight (RXST) Gets a Buy From BTIG
Analysts' Top Healthcare Picks: RxSight (RXST), Adaptive Biotechnologies (ADPT)
RxSight Analyst Ratings
RxSight Analyst Ratings
Oppenheimer Raises RxSight Price Target to $54 From $50, Maintains Outperform Rating